Previously we demonstrated that the sphingolipids ceramide and S1P (sphingosine 1-phosphate) regulate phosphorylation of the ERM (ezrin/radixin/moesin) family of cytoskeletal proteins [Canals, Jenkins, Roddy, Hernande-Corbacho, Obeid and Hannun (2010) J. Biol. Chem. 285, 32476-3285]. In the present article, we show that exogenously applied or endogenously generated S1P (in a sphingosine kinase-dependent manner) results in significant increases in phosphorylation of ERM proteins as well as filopodia formation. Using phosphomimetic and non-phosphorylatable ezrin mutants, we show that the S1P-induced cytoskeletal protrusions are dependent on ERM phosphorylation. Employing various pharmacological S1PR (S1P receptor) agonists and antagonists, along with siRNA (small interfering RNA) techniques and genetic knockout approaches, we identify the S1PR2 as the specific and necessary receptor to induce phosphorylation of ERM proteins and subsequent filopodia formation. Taken together, the results demonstrate a novel mechanism by which S1P regulates cellular architecture that requires S1PR2 and subsequent phosphorylation of ERM proteins.
INTRODUCTION
The ERM family of proteins, ezrin (82 kDa), radixin (80 kDa) and moesin (75 kDa), links the plasma membrane with the actin cortical cytoskeleton, and plays a role in regulating cell morphology, cell polarization and formation of plasma membrane protrusions such as filopodia and lamellipodia [1] . ERM proteins also work as scaffolding proteins for a growing list of plasma membrane and cytoskeletal proteins with roles in cell signal transduction, communicating with the extracellular matrix and with surrounding cells [2] . The study of the ERM family of proteins has captured significant interest as its members have been strongly related to an increasing number of cancers, including lung [3] , colon [4] and breast cancers [5] . The role of ezrin in cancer has been attributed to: (i) the binding and recruitment of plasma membrane receptors and other proteins such as FasL receptor (CD95) [6] , hyaluronan receptor (CD44) [7] , NHE1 (Na + /H + exchanger-1) [8] , cadherins [9] , integrins [10] , NF2 (neurofibromin 2; tumour suppressor protein merlin) [11] and others, most of which are also implicated in cancer progression [12] ; and (ii) promoting filopodia and lamellipodia formation, enhancing migration, invasion of surrounding tissues and adhesion to new metastatic settlements [13] .
The activation of ERM proteins is regulated by a change in protein conformation. In the inactive (closed) conformation, the N-terminus and the C-terminus interact with each other, and the ERM proteins remain soluble in the cytosol. Activation of ERM proteins requires N-terminal binding to plasma membrane PIP 2 (phosphatidylinositol 4,5-bisphosphate) and phosphorylation of a conserved C-terminal threonine (ezrin Thr 567 , radixin Thr 564 and moesin Thr 558 ). Phosphorylation of the conserved threonine creates a steric restriction between the Cand N-termini, which therefore cannot interact with each other, leading to the active (open) conformation. In this conformation, the N-terminus interacts with the plasma membrane, and the C-terminus interacts with the actin cortical cytoskeleton. Little is known about the control of ERM activation, although a few protein kinases have been reported to phosphorylate ERM in vivo {conventional and atypical PKC (protein kinase C) [3] , protein Rho kinase [11] , GRK2 (G-protein-coupled receptor kinase 2) [14] , myotonic dystrophy kinase-related Cdc42(cell division cycle 42)-binding kinase [15] and NIK (Nck-interacting kinase) [16] }, and only a couple of growth factors are known to activate ERM proteins. EGF (epidermal growth factor) [17] and PDGF (plateletderived growth factor) have been reported to be effectors that lead to ERM phosphorylation and activation [16] .
Our group demonstrated that the ERM family of proteins were acutely regulated by acid sphingomyelinase [18] , and more directly by the interconversion of the sphingolipids ceramide and S1P (sphingosine 1-phosphate) [19] . Ceramide has been widely associated with senescence, cell-cycle arrest and apoptosis [20] , and it was observed that ceramide induced dephosphorylation of ERM proteins. On the other hand, S1P, which has a role in enhancing inflammation, cell survival and cell migration [20] , was found to dramatically induce phosphorylation of ERM proteins [19] . Interestingly, both ERM proteins and S1P have been found to be up-regulated in some cancers [1, 21] .
Abbreviations used: CM, complete medium; DMEM, Dulbecco's modified Eagle's medium; ERM, ezrin/radixin/moesin; F, forward; FBS, fetal bovine serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein; GPCR, G-protein-coupled receptor; MEF, mouse embryonic fibroblast; NEO, neomycin; pERK, phosphorylated ERK (extracellular-signal-regulated kinase); pERM, phosphorylated ERM; R, reverse; RT, reverse transcriptase; S1P, sphingosine 1-phosphate; S1PR, S1P receptor; SCR, scrambled; SF, serum-free; siRNA, small interfering RNA; SK, sphingosine kinase; tMoe, total moesin; VSV-G, vesicular stomatitis virus glycoprotein; WT, wild-type. 1 These authors contributed equally to this work. 2 To whom correspondence should be addressed (email lina.obeid@stonybrookmedicine.edu).
In the cell, S1P is formed by the phosphorylation of sphingosine by one of two sphingosine kinases (SKs; SK1 and 2) and exported outside the cell whereby it can activate different receptors in an autocrine or paracrine manner. The pleiotropic effects of S1P in cells are mostly mediated through its interaction with five GPCRs (G-protein-coupled receptors), namely S1PR (S1P receptor) 1-S1PR5, which activate various combinations of G-proteins [20] . The finding of significant ERM phosphorylation in response to S1P prompted us to determine whether a specific SK isoform was involved, what S1PRs were involved in the process, and whether this resulted in activation of ERMs and induction of ERM-mediated responses.
In the present study, we found that S1P when exogenously applied or endogenously generated predominantly by the action of SK1 resulted in activation of ERM proteins leading to filopodia formation preferentially through activation of S1PR2. Using a combination of S1PR agonists and antagonists, as well as using siRNA (small interfering RNA) technology and knockout mice, we found that filopodia formation upon S1P treatment was pERM (phosphorylated ERM) dependent. This was confirmed by using ezrin phospho-mimetic and non-phosphorylatable mutants. The implications of these results are discussed.
MATERIALS AND METHODS

Materials
High-glucose DMEM (Dulbecco's modified Eagle's medium), FBS (fetal bovine serum), penicillin/streptomycin, rhodaminephalloidin and Superscript III First-Strand Synthesis kit were purchased from Invitrogen. Essentially fatty-acidfree BSA, and monoclonal anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase) antibody were from SigmaAldrich. D-erythro-S1P and D-erythro-sphingosine were from Avanti Polar Lipids. Anti-pERM, anti-moesin and anti-pERK [phosphorylated ERK (extracellular-signal-regulated kinase)] antibodies were from Cell Signaling Technology. Anti-VSV-G (vesicular stomatitis virus glycoprotein)-and anti-HRP (horseradish peroxidase)-labelled secondary antibodies were from Santa Cruz Biotechnology. Chemiluminescence kit was from ThermoScientific. Draq5 was purchased from Alexis Biochemicals. SYBR Green was purchased from Bio-Rad Laboratories. SEW-2871, JTE-013, BML-241 and FTY720-P were purchased from Cayman Chemical. S1PR2-GFP (green fluoresent protein) plasmid DNA was purchased from Origene. SKX (sphingosine kinase 1 inhibitor) was kindly provided by Sphynx Therapeutics.
Cell lines and culture conditions
HeLa cells were originally purchased from A.T.C.C. (Manassas, VA, U.S.A). Cells were maintained in DMEM supplemented with 10 % FBS and 1 % penicillin/streptomycin and incubated in standard culture conditions (37 • C and 5% CO 2 ). When FBSfree medium was used, the medium was supplemented with 0.1 % BSA, 1 % penicillin/streptomycin and 10 mM Hepes. In all cases, cells were serum starved overnight (16-18 h ) when approximately 75 % confluent before experimentation.
Generation of mouse embryonic fibroblasts S1PR2 mice were generously given by Richard L. Proia (National Institutes of Diabetes and Digestive and Kidney Disease, National Institutes of Health). MEFs (mouse embryonic fibroblasts) were generated from S1PR2
+ / − littermate matings in a C57BL6.129S background. MEFs were isolated from E13.5 embryos. Cells were maintained in high-glucose DMEM supplemented with 10 % FBS in standard culture conditions. For genotyping, genomic DNA was extracted using DNeasy Blood and Tissue kit (Qiagen) and 2 μl of DNA was combined with 1 μl each of either S1PR2 primer 1 and S1PR2 primer 2 or S1PR2 primer 1 and the NEO (neomycin) primer. This was combined with 21 μl of PCR Platinum SuperMix (Invitrogen) for a total reaction volume of 25 μl for PCR. The following primers (10 μM) from Integrated DNA Technologies were used for the detection of the wild-type or knockout S1PR2: S1PR2 primer 1, 5 -GCAGTGACAAAAGCTGCCGAATGCTGATG-3 ; S1PR2 primer 2, 5 -AGATGGTGACCACGCAGAGCACGTAGTG-3 ; and NEO primer, 5 -TGACCGCTTCCTCGTGCTTTACGGTA-TCG-3 . PCR was performed on a Biometra Thermocycler T3000 with the following reaction conditions for 40 cycles: 95
• C for 0.5 min; 55
• C for 0.5 min; and 72
• C for 0.5 min. PCR products were run separately for each set of primers on a 1.5 % agarose gel and visualized by UV transillumination. A 170-bp band indicated the WT (wild-type) S1PR2 allele and a band at 220 bp represented a knockout or NEO allele.
Immunoblotting
Immunoblotting was performed as described previously [19] . Following removal of medium, cells were immediately lysed in a buffer containing 1 % (w/v) SDS. Following harvest, cells were sonicated and boiled before proteins were separated via SDS/10 % PAGE (Tris/HCl) using the Bio-Rad Criterion system. Proteins were transferred to nitrocellulose membranes and blocked for at least 1 h with 5 % (w/v) non-fat dried skimmed milk powder in PBS/0.1 % Tween 20. Membranes were then incubated with primary antibody diluted 1:000 [pERM, tMoe (total moesin), VSV-G and pERK] or 1:6000 (GAPDH) at 4
• C overnight. Secondary antibody incubation and visualization were carried out following the manufacturer's protocol.
RNA interference
Gene silencing was carried out using siRNA, purchased from Qiagen, directed against human SK1, SK2 and S1PR2: SK1, 5 -AAGGGCAAGGCCTTGCAGCTC-3 ; SK2, Hs_SPHK2_5 FlexiTube siRNA SI00288561 (FlexiTube siRNA, Experimentally verified; Qiagen); and S1PR2, Hs_EDG5_6 FlexiTube siRNA SI02663227 (FlexiTube siRNA, Experimentally verified; Qiagen). SCR (scrambled) siRNA was used as a negative control: SCR, negative control siRNA (1027130; Qiagen). Transfections were carried out according to the manufacturer's protocol, using Qiagen HiPerFect transfection reagent. Briefly, HeLa cells were seeded into six-well plates (∼ 200 000 cells/well) and treated with 20 nM siRNA using Qiagen's fast-forward transfection protocol for adherent cells. Following 24 h of siRNA treatment, fresh medium was added. Experiments were carried out 24 h following replacement of medium and 48 h after siRNA transfection.
Real-time RT (reverse transcription)-PCR
RNA was harvested from cells using QIAShredder and RNeasy kits from Qiagen. RNA concentration was assessed by measuring absorbance at 260 nm. RNA (1 μg) was converted into cDNA using SuperScript III First-Strand Synthesis Systems from Invitrogen. cDNA was diluted 1:10 and 5 μl was used per 25 μl reaction. Each 25 μl real-time RT-PCR contained a ratio of 12.5:0.5:0.5:6.5 [SYBR Green/10 μM F (forward) primer/10 μM R (reverse) primer/distilled water]. Using a Bio-Rad iCycler, reactions detecting expression of human genes were carried out as previously explained [22] . Briefly, following 3 min at 95
• C, 40 cycles of (i) 10 s melt at 95
• C, (ii) 45 s annealing at 54
• C and (iii) 45 s extension at 68 • C were carried out. Reactions detecting mouse gene expression were carried out as described above; however, the annealing was performed at 60
• C. The following primers sequences were used to detect expression: human β-actin F, 5 -ATTGGCAATGAGCGGTTCC-3 ; human β-actin R, 5 -GG-TAGTTTCGTGGCCACA-3 ; hSK1 F, 5 -CTGGCAG-CTTCCTTGAACCAT-3 ; hSK1 R, 5 -TGTGCAGAGACA-GCAGGTTCA-3 ; hSK2 F, 5 -TTGCTCAACTGCTCACTG-3 ; hSK2 R, 5 -AGACAGGAAGGAGAAACAG-3 ; hS1PR1 F, 5 -TGCGGGAAGGGAGTATGTTTG-3 ; hS1PR1 R, 5 -AGGAA-GAGGCGGAAGTTATTGC-3 ; hS1PR2 F, 5 -CCCAACAAGG-TCCCAGGAACAC-3 ; hS1PR2 R, 5 -GCAACAGAGGATGA-CGATGAAGG-3 ; hS1PR3 F, 5 -AACAATAGCACGCACTC-TCC-3 ; hS1PR3 R, 5 -ATAAGAACACAGCCGGACAG-3 ; hS1PR4 F, 5 -TGGTGGTGCTGGAGAACTTG-3 ; hS1PR4 R, 5 -TGATGTTCACCAGGCAATAGTAG-3 ; hS1PR5 F, 5 -AA-ATGTGCCCATGTGTTCTAAGAAATG-3 ; hS1PR5 R, 5 -AAC-TACTCCTTCAGCTCC-3 ; mouse β-actin F, 5 -CGGGA-CCTCACAGACTACCTC-3 ; mouse β-actin R, 5 -AAC-CGCTCGTTGCCAATA-3 ; mS1PR1 F, 5 -CTCCACCGTGC-TCCCGCTCTA-3 ; mS1PR1 R, 5 -GGAGATGTTCTTGCGGA-AGGTCAGG-3 ; mS1PR2 F, 5 -GCGTGGTCACCATCTT-CTCC-3 ; mS1PR2 R, 5 -CGTCTGAGGACCAGCAACAT-C-3 ; mS1PR3 F, 5 -CATCGCCTTCCTCATCAGTATCTTC-3 ; mS1PR3 R, 5 -CACAATCACTACGGTCCGCCA-3 ; mS1PR4 F, 5 -GCACCTTGAGCATAACAGGA-3 ; mS1PR4 R, 5 -CGGGG-ACAGACTGAGAGAGG-3 ; mS1PR5 F, 5 -ACTGCTTAGGA-CGCCTGGAA-3 ; mS1PR5 R, 5 -CCGCACCTGACAGTAAA-TCCTT-3 . Using Q-Gene software [22] , DMEM (threshold cycle) values were normalized to β-actin and displayed as mean normalized expression.
Immunofluorescence and confocal microscopy
Immunofluorescence and laser-scanning confocal microscopy analysis was carried out as described previously with minor modifications [19] . HeLa cells were plated on to poly-Dlysine-coated 35-mm confocal dishes (MatTek Corporation). The following day, cells were serum starved overnight before being exposed to treatments. Cells were fixed using paraformaldehyde, washed and permeabilized with 0.1 % Triton X-100. Cells were blocked in 2 % human serum and incubated with primary antibodies (1:200) in 2 % serum overnight. Secondary antibody incubation was carried out according to the manufacturer's protocol. Using a LSM510 META confocal microscope (Carl Zeiss), images were obtained and then analysed using a free downloadable LSM Image Browser Software (http://www.zeiss.com).
Plasmid constructs and transient transfections
Full-length ezrin cDNA in VSV-G tagged pCB6 plasmid has been described previously [19] . Single mutations on ezrin T567D and T567A were generated using a QuikChange ® Site-Directed Mutagenesis kit from Stratagene. All plasmids were sequenced to confirm the sequence in Genewiz. Cells growing on 35-mm dishes were transfected with 1 μg of pCB6-Ezrin plasmid DNA or 1 μg of S1PR2-GFP plasmid using Lipofectamine TM (Invitrogen) or Effectene (Qiagen) transfection reagent (according to the manufacturer's instructions).
Cellular invasion assays
Cell invasion studies were carried out using the BD Biosciences Tumor Invasion System (345166) according to manufacturer's protocol, with minor changes. Briefly, following serum starvation for ∼ 4 h, the cells were trypsinized, washed twice with SF (serum-free) medium then resuspended at 200 000 cells/ml in SF medium. Then, 750 μl of appropriate medium or medium plus chemoattractant was placed in the well of a 24-well plate, followed by 500 μl of cell suspension in SF medium, in the presense or absence of 5 μM JTE013, in the apical chamber of the transwell insert. Cells were allowed to invade under normal cell culture conditions for 48 h. After 48 h, 500 μl of Calcein AM was added to wells of a fresh 24-well plate as per the manufacturer's protocol. Transwell inserts were removed carefully and cells in the apical chamber were wiped away using a cotton swab. Inserts were then added to the Calcein AM and incubated for 1 h at 37
• C. Cells were imaged under fluorescence microscopy and pictures of each quadrant of the underside of each transwell insert were taken and total invading cells were counted using NIH Image J software.
RESULTS
S1P induces ERM phosphorylation
In order to characterize sphingolipid-mediated activation of ERM proteins we performed time course and dose response studies of S1P treatment on ERM phosphorylation. Treating HeLa cells with 100 nM S1P induced acute and robust phosphorylation of ERM proteins occurring as early as 0.5 min and lasting for up to at least 15 min ( Figure 1A ). ERK phosphorylation is well known for occurring in response to S1P action on its receptors [23, 24] , therefore ERK was used as a positive control for S1P treatment. Treating HeLa cells with 100 nM S1P induced ERK phosphorylation by approximately 2 min, which was short-lived, decreasing after 5 min. Next, HeLa cells were treated with increasing concentrations of S1P for 5 min. ERM phosphorylation was increased in an S1P-dose-dependent manner ( Figure 1B ); treating cells with as little as 1 nM S1P induced robust phosphorylation of both ERK and ERM. Treating cells with increasing doses of S1P led to intensified ERM phosphorylation, becoming maximal at 100 nM. As described previously, S1P treatment also increased ERK phosphorylation in a dose-dependent manner [25] . These data demonstrate that exogenous S1P is able to induce phosphorylation of ERM proteins rapidly (faster and more robustly than induction of ERK phosphorylation) and at low nanomolar concentrations.
Next, and in order to assess the role of endogenously generated S1P, the effect of exogenously added sphingosine with or without knockdown of SK was determined [26] . Treatment with exogenous sphingosine, as well as driving the production of sphingosine at the plasma membrane using exogenous enzymes [19] led to SK-dependent generation of intra-and extra-cellular S1P (Supplementary Figures S1 and S2 at http://www.BiochemJ. org/bj/449/bj4490661add.htm). HeLa cells were pretreated with siRNA against SK1 or SK2, and as shown in Supplementary Fig ure S3 at http://www.BiochemJ.org/bj/449/bj4490661add.htm, both SK1 and SK2 were significantly knocked down. The SK knockdown was followed by treatment with 1 or 5 μM sphingosine for 10 min and evaluated for pERM. Sphingosine induced ERM phosphorylation in control siRNA-treated cells in a dose-dependent manner such that substantial ERM phosphorylation occurred in response to 1 μM sphingosine ( Figure 1C , lanes 2 and 3). HeLa cells pretreated with SK1 siRNA showed significantly less ERM phosphorylation in response to sphingosine ( Figure 1C , lanes 4-6), indicating that SK1-generated S1P is required for ERM phosphorylation in response to exogenously applied sphingosine. In contrast, cells treated with SK2 siRNA showed a notable increase in ERM phosphorylation in response to 1 and 5 μM sphingosine ( Figure 1C, lanes 7-9) , indicating that SK2 may be only partially involved in generation of S1P and ERM phosphorylation under these conditions. These data are in line with the differential levels of S1P generated by driving the production of sphingosine at the plasma membrane via treatment with exogenous bacterial sphingomyelinase and ceramidase in mouse embryonic fibroblasts generated from Figure S2 ) [19] ; whereas WT and SK2 − / − fibroblasts produced high levels of sphingosine and S1P on treatment with exogenous enzymes, SK1
− / − fibroblasts produced high levels of sphingosine yet substantially lower levels of S1P (Supplementary Figure S2) . These data confirm that exogenous S1P, as well as endogenous S1P generated by the action of SK, induce phosphorylation and activation of ERM proteins.
S1P induces ERM phosphorylation and translocation to newly formed filopodia
Next, in order to examine the cellular consequences of S1P-induced ERM, phosphorylation laser-scanning confocal microscopy was used. Under basal conditions HeLa cells exhibited very little pERM, which existed in a punctate pattern (Figure 2A) . Treating HeLa cells with 10 nM S1P for 10 min induced ERM phosphorylation and localization to newly formed filopodia. This is visualized in Figure 2 (B) by F-actin staining (red) and pERM staining (green) both of which localized to newly formed cytoskeletal processes, consistent with filopodial protrusions ( Figure 2B ). In order to better visualize pERM localization and filopodial protrusions, insets in Figure 2 show magnified areas of interest. Taken together, these results demonstrate that S1P-induced pERM is sufficient to induce the organization of filopodial protrusions.
Ezrin phosphorylation is necessary for S1P-induced filopodia formation
On the basis of the results described above, it became important to evaluate if ERM proteins are involved in S1P-mediated filopodia formation. C-terminal phosphorylation of Thr 567 , Thr 563 and Thr 558 of ezrin, radixin and moesin respectively has been shown to be important in ERM activation [28] ; therefore three different ezrin mutant constructs were utilized. WT ezrin, a non-phosphorylatable ezrin mutant and a phospho-mimetic ezrin mutant in a VSV-G vector were overexpressed in HeLa cells. The non-phosphorylatable ezrin mutant contains a T567A mutation, rendering it unable to be phosphorylated at the conserved, activating threonine residue [29] , whereas the phospho-mimetic ezrin mutant contains a T567D mutation that maintains ezrin in an open, active conformation [29] . Confocal microscopy was used to visualize total ezrin (VSV-G tag, green), F-actin (phalloidin, red) and nuclei (DRAQ5, blue) in control and S1P-stimulated cells. Under basal conditions, cells expressing WTezrin-VSV-G showed ezrin to be localized predominantly in the cytoplasm; however, stimulation with 10 nM S1P prompted remodelling of the actin network along with redistribution of ezrin to the plasma membrane and cellular processes, consistent with filopodia ( Figures 3A and 3B) . Similarly, non-treated cells overexpressing the T567A non-phosphorylatable ezrin mutant displayed ezrin located in the cytoplasm; however, in these cells S1P treatment failed to induce translocation of T567A-ezrin-VSV-G to the plasma membrane ( Figures 3C and 3D) . Importantly, as shown in Figure 3D with phalloidin staining (Factin, red), treating T567A-ezrin-VSV-G-expressing cells with 10 nM S1P did not lead to rearrangement of the actin network nor to the formation of cellular processes. These results suggest that ezrin phosphorylation is required for S1P-mediated cytoskeletal rearrangement and filopodia formation and that the TA mutant acts in a dominant-negative fashion. In contrast, cells expressing the T567D phospho-mimetic ezrin construct displayed ezrin localized to complex plasma membrane protrusions even under basal conditions ( Figure 3E ), and treatment with S1P did not induce further formation of cellular processes ( Figure 3F ). These findings, taken together, provide strong evidence that ezrin phosphorylation is required for S1P-induced cytoskeletal rearrangement and filopodia formation.
S1P induces phosphorylation of ERM proteins via S1P 2
Having established that S1P induces phosphorylation of ERM proteins and this phosphorylation event is required for S1P-induced cytoskeletal rearrangement and filopodia formation, we were interested in determining the mechanism by which S1P induces ERM phosphorylation. As mentioned above, S1P can signal through GPCRs as well as intracellularly [25] and the expression pattern of S1PRs in a given cell type largely determines the outcome of S1P treatment. Therefore we examined S1PR expression in the HeLa cells used in our experiments (Supplementary Figure S4 at http://www.BiochemJ.org/bj/449/ bj4490661add.htm). In the present study, we were able to detect the presence of all five S1PRs; of note, the expression levels of receptors cannot be compared with one another owing to potential differences in primer efficiencies. Given the low doses and short times at which S1P is capable of phosphorylating ERM (Figure 1 ), we first evaluated the possible role of S1PRs in this process by relying on well-characterized pharmacological approaches. HeLa cells were treated with FTY720-P, an agonist for four of the five S1PRs: S1PR1, S1PR3, S1PR4 and S1PR5 [30] ; in accordance with our previous data, HeLa cells treated with 10 nM S1P exhibited a robust increase in ERM phosphorylation, with a concomitant increase in ERK phosphorylation ( Figure 4A ). On the other hand, whereas ERK was phosphorylated in response to 10, 100 or 1000 nM FTY720-P suggesting that the treatment activated S1PRs, FTY720-P was unable to induce ERM phosphorylation ( Figure 4A ). These data appear to rule out S1PR1, S1PR3, S1PR4 and S1PR5 as the main receptors responsible for S1P-mediated ERM phosphorylation. To consolidate evidence that S1P-mediated ERM phosphorylation is S1P1-independent, HeLa cells were treated with a specific agonist of the S1P 1 receptor, SEW-2871 [31] . Although S1P was able to induce phosphorylation of both ERM and ERK, treatment with 1 or 10 μM SEW-2871 was only able to phosphorylate ERK suggesting that S1P does not induce ERM phosphorylation via S1PR1 ( Figure 4B ).
We next examined the involvement of S1PR3 in S1P regulation of ERM proteins using the S1PR3-specific antagonist BML-241 [32] . In order to reinforce our data suggesting that S1P-induced ERM phosphorylation is S1PR3-independent, HeLa cells were pretreated for 1 h with vehicle, 1 μM or 7.5 μM BML-241 followed by 10 min of S1P treatment ( Figure 4C ). S1P maintained its ability to induce ERM phosphorylation in the presence of an S1P 3 -specific antagonist, indicating that the S1PR3 is not involved in ERM phosphorylation ( Figure 4C ). In order to assess the role of S1PR2 in ERM phosphorylation, we used the S1PR2-specific antagonist JTE-013 [33] and evaluated pERM following S1P treatment. HeLa cells were pretreated for 1 h with vehicle, 1 μM or 10 μM S1PR2-specific antagonist and then exposed to 10 nM S1P for 10 min; pERM, pERK and tMoe levels were evaluated via Western blotting ( Figure 4D ). JTE-013 inhibited S1P-stimulated ERM phosphorylation in a dose-dependent manner such that 1 μM JTE-013 notably inhibited S1P-mediated pERM, whereas substantial inhibition was shown with 10 μM JTE-013 ( Figure 4D) indicating that S1PR2 plays a pivotal role in ERM phosphorylation by exogenous S1P, as well as endogenously generated S1P (Supplementary Figure S5 at http://www.BiochemJ. org/bj/449/bj4490661add.htm). Interestingly, S1PR2-specific inhibition prevented S1P-mediated ERM phosphorylation in U87 glioblastoma cells as well (Supplementary Figure S6 at http:// www.BiochemJ.org/bj/449/bj4490661add.htm). In addition, we examined the role of S1PR2 in endogenously generated S1P-induced pERM. As described previously, HeLa cells were pretreated with vehicle or 5 μM S1PR2-specific antagonist, therefore these results suggest that ERM phosphorylation by S1P occurs independently of the S1PR1, S1PR3, S1PR4 and S1PR5, whereas S1PR2 is essential for endogenously generated or exogenously added S1P-induced phospho-ERM.
In order to further solidify S1PR2 as the receptor via which S1P mediates ERM phosphorylation, HeLa cells were treated with
Figure 4 Effect of pharmacological modulation of S1PRs on S1P-mediated phosphorylation of ERM proteins
HeLa cells were starved overnight and treated with (A) 100 nM S1P or the indicated doses of FTY720-P (agonist for S1PR1, S1PR3, S1PR4 and S1PR5) for 10 min or with (B) the indicated amounts of SEW-2871 (specific agonist for S1PR1) for 10 min. Blots are representative of two experiments. Serum starved HeLa cells were treated with 10 nM S1P for 10 min following 1 h of pretreatment with the indicated amounts of (C) S1PR3-specific antagonist, BML-241 or (D) S1PR2-specific antagonist, JTE-013. pERM, pERK and GAPDH and tMoe levels were analysed via Western blotting. Blots are representative of four experiments. veh, vehicle. siRNA against the S1PR2 followed by S1P treatment. As shown in Figure 5 (A), cells pretreated with control siRNA responded to 10 nM S1P with robust ERM and ERK phosphorylation. On the other hand, cells pretreated with S1PR2 siRNA responded notably less to S1P with a significant decrease in both ERM and ERK phosphorylation; these results support the above data ( Figure 4D ) that S1PR2 is necessary for ERM phosphorylation in response to S1P under these conditions. To evaluate the role of S1PR2 in ERM phosphorylation mediated by endogenously generated S1P, cells were treated with siRNA for S1PR2 and increasing concentrations of sphingosine were added ( Figure 5B ). S1PR2 siRNA was able to significantly inhibit sphingosine-mediated pERM, further suggesting a role for S1PR2 in endogenously generated S1P-induced ERM phosphorylation ( Figure 5B) . Finally, to consolidate the role of S1PR2 in ERM phosphorylation, cell lines derived from MEFs that were WT ( + / + ), heterozygous ( − / + ) or homozygous negative ( − / − ) for the S1PR2 receptor were established. Just as in HeLa cells, MEFs were starved overnight and treated with 10 nM S1P for 10 min. Following S1P treatment, WT and heterozygous MEFs exhibited a robust phosphorylation of ERM; however, the S1PR2-knockout MEFs showed a significantly abrogated response to S1P treatment ( Figure 5C ). These finding further solidify S1PR2 as the receptor through which S1P induces ERM activation.
Lastly, and in addition to the above techniques, using a GFPtagged S1PR2 construct, S1PR2 activation and internalization upon S1P treatment was examined. HeLa cells were transfected with 1 μg of S1PR2-GFP plasmid and exposed to S1P in the presence or absence of 5 μM JTE-013. Following fixation, receptor localization was visualized using confocal microscopy. In control untreated cells, S1PR2 remained primarily on the plasma membrane with little recycling observed ( Figure 6A ). On the other hand, after treatment with 100 nM S1P for 5 min, the amount of receptor on the membrane decreased and very small punctate spots in the cytosol became visible, indicative of S1PR2 activation and internalization ( Figure 6B ). In line with acute activation (as early as 30 s) of ERM proteins by S1P, receptor
Figure 6 S1P-mediated S1PR2 internalization
HeLa cells were transfected with 1 μg S1PR2-GFP plasmid. At 24 h following transfection, cells were serum starved overnight. The cells were exposed to (A) no treatment, (B) 100 nM S1P for 5 min or (C) 1 h of pretreatment with 5 μM JTE-013 followed by 100 nM S1P for 5 min. Cells were fixed and imaged using confocal microscopy. Images are representative of two or more experiments.
internalization is observed as early as 30 s following treatment with exogenous S1P (Supplementary Figure S7A at http://www. BiochemJ.org/bj/449/bj4490661add.htm). Moreover, S1PR2 internalization occurs in an SK-dependent manner, such that in the presence of SK1 and 2, sphingosine was unable to induce receptor internalization (Supplementary Figure 7B) . In line with the above observations, cells pretreated with S1PR2 antagonist showed substantially less receptor internalization with S1P treatment ( Figure 6C ). These data provide strong pharmacological, genetic and visual evidence for S1PR2 involvement in S1P-mediated ERM phosphorylation.
S1P induces filopodia formation via S1PR2-dependent ERM phosphorylation
Given the data described above, it became necessary for us to determine the mechanism by which S1P-mediated pERMdependent filopodia formation occurs. In order to address this, we used a pharmacological approach to examine the involvement of S1PRs in S1P-induced pERM-required filopodia formation. As described above, we treated HeLa cells with FTY720-P and examined cytoskeletal rearrangements, including filopodia formation. Briefly, 10 nM FTY720-P was added to cells for 10 min, cells were then fixed, permeabilized and stained for Factin (phalloidin, red), pERM (green) and nuclei (DRAQ5, blue). No changes in ERM phosphorylation or cellular morphology, including filopodial protrusions, were observed in cells exposed to FTY720-P ( Figure 7D ). These results are in line with the above observations ( Figure 4A ) suggesting that FTY720-P is unable to induce ERM phosphorylation. Next, we examined the role of S1PR2 in S1P-induced pERM-mediated filopodia formation. As seen in Figure 7 (A), untreated HeLa cells showed punctate lowlevel cytoplasmic expression of pERM. S1P induced a robust and rapid increase in ERM phosphorylation and localization to newly formed cellular processes ( Figure 7B) ; however, treating cells with FTY720-P did not ( Figure 7C ). Pretreating cells for Figure 7 Effect of inhibition of S1PR2 on S1P-mediated pERM and filopodia formation HeLa cells were serum deprived and received (A) no treatment, (B) 10 nM S1P for 10 min, (C) 10 nM FTY720-P for 10 min, or (D) 1 h of treatment with 1 μM JTE-013, followed by treatment with 10 nM S1P for 10 min. Cells were fixed and phospho-ERM (green), nuclei (DRAQ5, blue) and F-actin (phalloidin, red) were visualized using confocal microscopy. Scale bars represent 50 μm. Images, showing the presence or absence of filopodia, are enlarged in insets. Images are representative of at least two independent experiments. 1 h with 1 μM S1PR2-specific antagonist, JTE-013, abrogated S1P-induced ERM phosphorylation (shown via Western blotting in Figure 4D and with confocal microscopy in Figure 7D ), as well as S1P-mediated filopodia formation ( Figure 7D ). These data highlight the role of S1PR2 in S1P-mediated ERM activation and filopodia formation.
Inhibition of S1PR2 induces cellular invasion
Lastly, and in order to determine the role of S1PR2-dependent, S1P-induced ERM activation and filopodia formation in metastatic behaviour, we examined the invasiveness of cells in response to S1P in the presence or absence of S1PR2-specific inhibitor, JTE-013. Using matrigel-coated transwell dishes, we examined cellular invasion towards CM (complete medium), SF medium or SF medium containing 500 nM S1P. HeLa cells were serum starved for 4-6 h, trypsinized and washed with SF medium before plating. A total of 100 000 cells in SF medium or SF medium containing 5 μM JTE-013 were then added to the apical chamber of the transwell system and cells were allowed to invade for 48 h. Following 48 h, cells were stained and counted. As expected, significant cellular invasion was observed in CM, whereas little to no invasion occurred in SF medium in the presence or absence of JTE-013 (Figure 8) . Interestingly, SF medium containing S1P was unable to induce invasion above that of SF medium, suggesting that S1P-activation of ERM proteins and subsequent filopodia formation does not lead to cellular invasion (Figure 8 ). On the other hand, cells exposed to S1PR2 antagonist significantly invaded towards S1P, suggesting that inhibition of S1PR2 promotes invasion towards S1P (Figure 8 ). These data in concert with the previously presented data provide insight into the mechanism by which S1P induces filopodia formation and inhibition of invasion: through S1PR2-dependent phosphorylation of ERM proteins.
DISCUSSION
In the present article, we describe the mechanism of S1P-induced ERM-dependent filopodia formation. Exogenously added or endogenously generated S1P was sufficient to induce robust ERM phosphorylation. Functionally, S1P induced cytoskeletal remodelling, more explicitly, the formation of cellular protrusions and filopodia, in a process that required activation of ERM
Figure 8 Role of S1P/S1PR2 in cellular invasion
HeLa cells were plated, in the presence or absence of 5 μM JTE-013, in the apical chambers of matrigel-coated transwell plates and allowed to invade for 48 h towards CM, SF medium or 500 nM S1P. Cells were fluorescently labelled and photographed before counting. Results are means+ − S.D.; n 3; Student's t test used to assess evaluate significance.
proteins by phosphorylation of the C-terminal threonine residue. Using numerous approaches, we show that S1P-induced, pERM-mediated filopodia formation occurs through activation specifically of S1PR2. Collectively, our results characterize a novel pathway in which SK/S1P regulates changes in cellular architecture that require S1PR2 and subsequent phosphorylation of ERM proteins.
S1P-induced cytoskeletal rearrangement is dependent on ERM phosphorylation
S1P has been shown to govern many mechanical properties of the cell, such as regulation of cortical actin assembly and consequent lamellipodial protrusion formation [34, 35] ; however, the mechanisms have remained elusive. In the present study, we found that S1P treatment induced vast changes in cell structure with an abundance of cytoskeletal protrusions. Although less well-characterized serine and tyrosine ERM phosphorylation sites have been identified [17, 36] , the C-terminal threonine residue (ezrin Thr 567 , radixin Thr 564 and moesin Thr 558 ) is known to be the phosphorylation site required for ERM activation. Using the T567A non-phosphorylatable ezrin mutant, we provide evidence that S1P leads to phosphorylation of this specific site and that this C-terminal phosphorylation is required for S1P-induced filopodia formation. The T567A ezrin mutant not only failed to translocate c The Authors Journal compilation c 2013 Biochemical Society to membrane protrusions, but also prevented their formation following S1P treatment, thus functioning as a dominantnegative. Our previous work has identified sphingolipids as regulators of ERM [19] ; furthermore we have identified a direct cellular biological process induced by sphingolipids requiring the activation of ERM proteins.
S1PR2 is required for S1P-induced pERM
Using a variety of pharmacological reagents, such as specific agonists and antagonists of S1PRs, siRNA and genetic knockouts, we demonstrate that S1PR2 is the predominant receptor involved in mediating the effects of S1P on ERM phosphorylation. Initially, the short time and low dose required for ERM phosphorylation in our study strongly suggests a S1PR-mediated response, similar to that of acute S1PR-mediated calcium release in lung epithelial cells, which occurs as early as 20 s after S1P treatment [37] FTY720-P, which acts as an agonist to receptors 1, 3, 4 and 5, was unable to induce phosphorylation of ERM, suggesting that these receptors are not involved in S1P-induced pERM. Also, the receptor expression profile of the MEFs used in the current study revealed no detectable expression of S1PR4 or S1PR5, suggesting that the S1P-mediated pERM signal in these cells is unlikely to be through activation of S1PR4 or S1PR5. Activation of S1PR1 with SEW-2871 did not induce ERM phosphorylation; likewise, selective inhibition of S1PR3 did not prevent S1P-mediated pERM. Moreover, down-regulation of S1PR2 with siRNA and the use of S1PR2-null MEFs consolidated our conclusion by showing inhibition of ERM phosphorylation following sphingosine or S1P treatment. Alternatively, minor contributions from other less well-characterized S1PRs cannot be conclusively excluded by the approaches used. Importantly, S1P-induced pERM is not cell-type specific as we were able to show ERM phosphorylation in a plethora of cell types including breast and lung cancer cells, glioblastoma cells, chondrogenic cells and fibroblasts (Supplementary Figure S8 at http://www.BiochemJ. org/bj/449/bj4490661add.htm). In addition, we were able to identify S1PR2 as the necessary receptor in U87 glioblastoma cells, suggesting that the involvement of S1PR2 in S1P-mediated pERM is also not cell-type specific (Supplementary Figure S6) . On the basis of these observations, we conclude that S1P activates ERM proteins via S1PR2 and speculate that this may be one of the main functions of S1PR2 owing to the robust and rapid manner in which it occurs.
Interestingly, and in contrast with the role of S1PR2 in mediating S1P effects on ERMs and membrane protrusions, it does not appear to be involved in mediating the effects of S1P on stress fibre formation [38] . Thus, although FTY720-P was unable to promote formation of cellular processes, it did induce the formation of stress fibres (results not shown), suggesting that FTY720-P functions similarly to S1P in the formation of stress fibres yet not in promotion of cellular protrusions. Therefore it appears that distinct S1PRs are required for regulating protrusions versus stress fibre formation. Since ERM proteins have been well documented to induce cell migration, we were surprised to find that ERM proteins are phosphorylated via S1PR2. S1PR2 has been described as an inhibitor of migration, leaving us curious about the function of S1PR2-mediated pERM. In the present study, S1P-induced ERM activation and filopodia formation did not lead to cellular invasion; in fact, S1P signalling via S1PR2 prevented cellular invasion such that S1PR2 inhibition promoted invasion. This is in line with previous studies suggesting that S1PR2 blocks S1P-induced invasion and migration. Additional studies examining the role of S1P in the differential regulation of ERM proteins in basal versus pathological conditions will be necessary in order to fully understand the interplay between the two (see e.g. [51] ).
Implications
The results from our study have many important biological implications. ERM proteins and S1P share several cellular roles, including organization of architecture and formation of structures such as lamellipodia and filopodia that are known to influence subsequent adhesion, migration, invasion, survival and proliferation [1, [39] [40] [41] .
The results of the present study have important implications for cancer including tumour progression, metastasis and perhaps evasion from apoptosis. Much is known about the involvement of the SK/S1P pathway in various stages of cancer [42] . First, SK has been implicated in initiation of cancer by its ability to function as a Ras-dependent oncogene [43] . As previously mentioned, the SK/S1P pathway plays a major role in inflammation, which is beginning to be linked to certain types of cancers [44] . S1P has been associated with cancer maintenance through its pro-growth and survival properties [45, 46] , as well as cancer progression through its cell migratory functions. Remarkably, ERM proteins have been implicated in most of the aforementioned processes. ERM proteins have been shown to be overexpressed in some cancers, positively correlating with cancer cell survival, proliferation, migration, adhesion and invasion. The results of the present study provide a more specific link between S1P, ERM phosphorylation and filopodial formation. We put forth the idea that phosphorylation of ERM is perhaps a major mechanism by which the SK/S1P pathway contributes to cancer cell development and metastasis.
Although the results of the present study suggest that S1P signalling via S1PR2 inhibits invasion, we suggest that global activation of ERM, around the entire periphery of the cell, leads to increased cell-cell adhesion such as that which occurs in epithelial sheet formation. Filopodia formation has been shown to promote cell-cell contacts and induce a phenomenon known as 'adhesion zippering', whereby formation of mature adherens junctions by interdigitated filopodia from neighbouring cells align and adhere cells in a calcium-dependent manner [47, 48] . Interestingly, S1PR2 has been linked to calcium mobilization in overexpression studies [49] , as well as in knockout studies [50] . These data are complementary to the findings that S1P promotes endothelial barrier function via regulation of ERM proteins [51] . Further exploration of the role of S1P/S1PR2 in the formation of cell-cell adhesions may prove useful in the area of wound healing. In contrast with its role in the inhibition of invasion, there is evidence suggesting that S1PR2 actually contributes to cancer progression and metastasis by enhancing cell adhesion and subsequent invasion [39] . It will be interesting to explore the role of ligand-induced activation of SK and subsequent regulation of ERM proteins. Perhaps ligand-induced cellular polarization, such as that which occurs with various chemoattractants, and localized activation of the SK/S1P pathway leads to asymmetrical activation of ERM proteins, driving cell migration and/or invasion. The cellular localization of S1PR2 indubitably affects the outcome of its activation, and this may account for the controversy surrounding the role of S1PR2 in cellular invasion and migration.
In lymphocyte biology, many of the aforementioned biologics are important components of inflammation and immunity, particularly with regard to migrating lymphocytes. For example, S1P is known to be involved in lymphocyte egress, chemotaxis and homing through S1PR1-mediated migration, such that down-regulation of S1PR1 results in lymphopaenia [52, 53] . Interestingly, ERM proteins have been extensively studied in the polarization and migration of lymphocytes [54] . Phosphorylated ezrin has been shown to localize to the rear of EL4.G8 Tlymphoma cells during chemotaxis, and this rear localization of phosphorylated ezrin may potentially function in retraction of the lagging edge of the cell [55] . In that study, T-cells expressing the T567D phospho-mimetic ezrin mutant had significantly larger trailing protrusions compared with cells expressing WT ezrin and T567A non-phosphorylatable ezrin mutant [56] . On the other hand, pERM proteins have also been shown to localize to lamellipodia at the leading edge of B-lymphoma cells to promote forward protrusion [57] . Whether at the leading or lagging edge of lymphocytes, ERM proteins have been shown to play a major role in lymphocyte polarization, chemotaxis and homing, providing overlapping functions of S1P and ERM proteins.
Another intriguing direct connection emerges in cochlear function. Maintenance of cell junctions is an important function of both S1P and ERM proteins, and this is highlighted best in the preservation of cochlear integrity. S1PR2 receptor-null mice exhibit a progressive hearing loss phenotype and are deaf by 1 month of age owing to deterioration in the barrier epithelium of the cochlea [58, 59] ; interestingly, radixin-knockout mice also experience deafness as a result of improper structural maintenance of cochlear stereocilia [58, 60] . Thus the results of the present study establishing S1P as a potent and robust inducer of ERM phosphorylation raise the intriguing possibility that ERM regulation may be a major function of the SK/S1P pathway in the cochlea.
Additionally, both S1P and ERM proteins have been implicated in neovasculogenesis, angiogenesis and vascular function and constitute another example of how S1P and ERM proteins may co-ordinate and/or share biological functions. Specifically, SK1/SK2-double-knockout mice and S1PR1-knockout mice die by embryonic day 13.5 owing to haemorrhage brought on by improper blood vessel formation [61] ; remarkably, ERM proteins play a major role in promoting endothelial cell polarity, cell migration, in vivo lumen formation, cell-cell adhesion and endothelial barrier function [1] providing compelling evidence of an additional fundamental S1P-dependent biology that may be mediated by ERM proteins.
Lastly, these results reveal potential novel therapeutic targets for the treatment of cancer, inflammation and other diseases involving deregulation of SK/S1P and/or ERM proteins. The SK/S1P pathway is essential to life as evidenced by the lethality of SK1/SK2 and S1PR1 gene knockout in mice. There has yet to be a triple knockout of ezrin, radixin and moesin; however, given the number of important cellular processes in which they are involved, it is likely that devastating phenotypes would be observed. Targeting the SK/S1P pathway therapeutically has proven to be difficult in that the basal homoeostatic functions carried out by SK/S1P are affected; similarly, therapeutically targeting ERM proteins will disrupt the major normal cellular functions to which they contribute: for example, spindle formation and cytokinesis [2] . Our findings that S1P induction of pERM occurs through the S1PR2 receptor expose a novel target for various therapies; specific antagonists of S1PR2 currently exist and are well tolerated in animal studies [62] and knockout of the S1PR2 gene in mice is not lethal [59, 63] . In conclusion, we have demonstrated a role for ERM proteins in mediating signals of the SK/S1P/S1PR2 pathway and suggest that localization of S1PR2 and subsequent localized activation of ERM proteins may play a role in the cellular response to S1P. Figure S2 Driving the production of sphingosine at the plasma membrane results in SK-dependent S1P generation (A) HeLa cells were exposed to scrambled siRNA or 10 nM SK1 plus 10 nM SK2 siRNA. Following 48 h of siRNA exposure, cells were serum starved and treated with 0.1 units/ml bSMase (bacterial sphingomyelinase) for 2 min followed by bacterial ceramidase (bCDase) for 8 min. Cellular levels of sphingosine and S1P were then measured by MS. (B) WT, SK1
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− / − or SK2 − / − MEFs were treated with bSMase for 10 min, bCDase for 10 min or bSMase for 2 min followed by bCDase for 8 min. The indicated lipids were measured using MS and pmol of sphingolipid were normalized to nmol of lipid phosphate. CDase; ceramidase; Ctl, control; SM, sphingomyelin.
c The Authors Journal compilation c 2013 Biochemical Society S1P induces filopodia via S1PR2 activation of ERM proteins U87 glioblastoma cells were starved overnight and treated with (A) 100 nM S1P for 0-60 min or 1-1000 nM S1P for 10 min and pERM levels determined by Western blotting. (B) U87 glioblastoma cells were serum starved overnight and stimulated with 100 nM S1P following 1 h pretreatment with VPC23019, JTE013, VPC23019 and JTE013 or BML241. SEW2871 treatment was for 10 min at 1 μM. pERM, pERK and tMoe levels were determined by Western blotting.
Figure S7 S1P-induced S1P2R internalization S1P2R-GFP plasmid DNA was overexpressed in HeLa cells. At 24 h following transfection, cells were starved overnight and then received (A) no treatment, treatment with 100 nM S1P for 30 s or (B) 1 h of pretreatment with 15 μM SK1-2 or vehicle followed by 5 μM sphingosine for 5 min. Cells were fixed and receptor localization assessed via confocal microscopy.
